Epidemiology of Hematologic Malignancies in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tietsche de Moraes Hungria Vania, Chiattone Carlos, Pavlovsky Miguel, Abenoza Lina M, Agreda Gladys P, Armenta Jorge, Arrais Celso, Avendaño Flores Oscar, Barroso Fernando, Basquiera Ana L, Cao Carmen, Cugliari Maria S, Enrico Alicia, Foggliatto Laura M, Galvez Kenny M, Gomez David, Gomez Alvaro, de Iracema Daniel, Farias Danielle, Lopez Lineth, Mantilla William Armando, Martínez Deborah, Mela Maria Jose, Miguel Carlos E, Ovilla Roberto, Palmer Luis, Pavlovsky Carolina, Ramos Christian, Remaggi Guillermina, Santucci Rodrigo, Schusterschitz Sergio, Sossa Claudia Lucia, Tuna-Aguilar Elena, Vela Jorge, Santos Telma, de la Mora Odin, Machnicki Gerardo, Fernandez Mariana, Barreyro Paula
Аннотация
METHODS: This study was a multicenter, retrospective, medical chart review of patients with MM, CLL, and NHL in Latin America identified between January 1, 2006, and December 31, 2015. Included were adults with at least 1 year of follow-up (except in cases of death within 1 year of diagnosis) treated at 30 oncology hospitals (Argentina, 5; Brazil, 9; Chile, 1; Colombia, 5; Mexico, 6; Panama/Guatemala, 4).
RESULTS: Of 5,140 patients, 2,967 (57.7%) had NHL, 1,518 (29.5%) MM, and 655 (12.7%) CLL. Median follow-up was 2.2 years for MM, 3.0 years for CLL, and 2.2 years for NHL, and approximately 26% died during the study observation period. Most patients had at least one comorbidity at diagnosis. The most frequent induction regimen was thalidomide-based chemotherapy for MM and chlorambucil with or without prednisone for CLL. Most patients with NHL had diffuse large B-cell lymphoma (DLBCL; 49.1%) or follicular lymphoma (FL; 19.5%). The majority of patients with DLBCL or FL received rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
CONCLUSION: The HOLA study generated an unprecedented level of high-quality, real-world evidence on characteristics and treatment patterns of patients with hematologic malignancies. Regional disparities in patient characteristics may reflect differences in ethnoracial identity and level of access to care. These data provide needed real-world evidence to understand the disease landscape in Latin America and may be used to inform clinical and health policy decision making.